{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:08:42Z","timestamp":1770916122357,"version":"3.50.1"},"reference-count":260,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012657","type":"journal-article","created":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T15:53:08Z","timestamp":1494258788000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis"],"prefix":"10.1002","volume":"2017","author":[{"given":"Jasvinder A","family":"Singh","sequence":"first","affiliation":[{"name":"Birmingham VA Medical Center; Department of Medicine; Faculty Office Tower 805B 510 20th Street South Birmingham AL USA 35294"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alomgir","family":"Hossain","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute; Cardiovascular Research Methods Centre; 40 Ruskin Street Room H-2265 Ottawa ON Canada K1Y 4W7"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy S","family":"Mudano","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham; Department of Medicine - Rheumatology; Birmingham USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Tanjong Ghogomu","sequence":"additional","affiliation":[{"name":"University of Ottawa; Bruy\u00e8re Research Institute; 43 Bruy\u00e8re St Annex E, room 213 Ottawa ON Canada K1N 5C8"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E","family":"Suarez-Almazor","sequence":"additional","affiliation":[{"name":"The University of Texas, MD Anderson Cancer Center; Department of General Internal Medicine; 1515 Holcombe Blvd Unit 1465 Houston Texas USA 77030"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachelle","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; Monash Department of Clinical Epidemiology, Cabrini Hospital; Suite 41, Cabrini Medical Centre 183 Wattletree Road Malvern Victoria Australia 3144"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara J","family":"Maxwell","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital - General Campus; Centre for Practice-Changing Research (CPCR); 501 Smyth Road, Box 711 Ottawa ON Canada K1H 8L6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa; Department of Medicine; Ottawa ON Canada K1H 8M5"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A","family":"Wells","sequence":"additional","affiliation":[{"name":"University of Ottawa; Department of Epidemiology and Community Medicine; Room H1281 40 Ruskin Street Ottawa ON Canada K1Y 4W7"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,5,8]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD012657-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1467\u2013147","DOI":"10.1002\/art.24106","article-title":"Effect of the early use of the anti\u2013tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis","volume":"59","author":"Bejarano","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012657-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1971\u20134","DOI":"10.1093\/rheumatology\/keq194","article-title":"Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis","volume":"49","author":"Bejarano","year":"2010","journal-title":"Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD012657-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER Study. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012657-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"844\u201350","DOI":"10.1136\/annrheumdis-2012-201612","article-title":"Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-na\u00efve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study","volume":"72","author":"Detert","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"10.1002\/14651858.CD012657-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"3919\u201327","DOI":"10.1002\/art.23055","article-title":"Treatment of early rheumatoid arthritis. A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone","volume":"56","author":"Durez","year":"2007","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012657-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","article-title":"Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial","volume":"372","author":"Emery","year":"2008","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD012657-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"2272\u201383","DOI":"10.1002\/art.24638","article-title":"Golimumab, a human anti\u2013tumor necrosis factor monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis. Twenty-four\u2013week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012657-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/annrheumdis-2011-201247","article-title":"Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study","volume":"72","author":"Kavanaugh","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/ajcn\/84.6.1463","article-title":"Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis","volume":"84","author":"Marcora","year":"2008","journal-title":"American Journal of Clinical Nutrition"},{"issue":"1","key":"10.1002\/14651858.CD012657-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2013-203440","article-title":"Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)","volume":"73","author":"Nam","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1136\/annrheumdis-2013-204882","article-title":"A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial","volume":"73","author":"Nam","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD012657-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.20712","article-title":"Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal. Results from a twelve-month randomized, double-blind, placebo-controlled trial","volume":"52","author":"Quinn","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"11","key":"10.1002\/14651858.CD012657-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1136\/annrheumdis-2013-203497","article-title":"Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial","volume":"73","author":"Rantalaiho","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0014|cit14","first-page":"1429\u201334","article-title":"Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial","volume":"49","author":"Soubrier","year":"2009","journal-title":"Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD012657-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"3432\u201343","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis a randomized, controlled trial","volume":"50","author":"Clair","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012657-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"351\u20137","DOI":"10.1136\/annrheumdis-2011-200170","article-title":"Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE","volume":"71","author":"Tak","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD012657-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/annrheumdis-2012-202433","article-title":"Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study","volume":"73","author":"Takeuchi","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.3899\/jrheum.120541","article-title":"Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis - a randomized trial","volume":"39","author":"Tam","year":"2012","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1870\u20137","DOI":"10.1136\/ard.2008.101121","article-title":"Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors","volume":"68","author":"Westhovens","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0020|cit20","first-page":"37","article-title":"A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis","volume":"33","author":"Abe","year":"2006","journal-title":"The Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD012657-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/annrheumdis-2013-204537","article-title":"A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial","volume":"74","author":"Axelsen","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2474-14-13","article-title":"Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis","volume":"14","author":"Bae","year":"2013","journal-title":"BMC Musculoskeletal Disorders"},{"issue":"22","key":"10.1002\/14651858.CD012657-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012657-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/annrheumdis-2013-204427","article-title":"Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)","volume":"74","author":"Bingham","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"10.1002\/14651858.CD012657-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/acr.22638","article-title":"Etanercept-methotrexate combination therapy initiators have greater adherence and persistence than triple therapy initiators with rheumatoid arthritis","volume":"67","author":"Bonafede","year":"2015","journal-title":"Arthritis Care and Research (Hoboken)"},{"issue":"9865","key":"10.1002\/14651858.CD012657-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","article-title":"Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial","volume":"74","author":"Burmester","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0929-6646(09)60071-1","article-title":"Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis","volume":"108","author":"Chen","year":"2009","journal-title":"Journal of the Formosan Medical Association"},{"issue":"16","key":"10.1002\/14651858.CD012657-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.3760\/cma.j.issn.0366-6999.20140670","article-title":"Tartrate-resistant acid phosphatase 5b is a potential biomarker for rheumatoid arthritis: a pilot study in Han Chinese","volume":"127","author":"Cheng","year":"2014","journal-title":"Chinese Medical Journal"},{"key":"10.1002\/14651858.CD012657-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/rheumatology\/ker519","article-title":"Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX","volume":"51","author":"Choy","year":"2012","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis and Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD012657-BIB0032|cit32","first-page":"523","article-title":"A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee","volume":"30","author":"Cohen","year":"2003","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/ard.2003.016014","article-title":"A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate","volume":"63","author":"Cohen","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"10.1002\/14651858.CD012657-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012657-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/ard.2005.049650","article-title":"Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison","volume":"65","author":"Combe","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1136\/annrheumdis-2012-201611","article-title":"Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial","volume":"72","author":"Conaghan","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD012657-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1136\/annrheumdis-2013-204762","article-title":"The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy","volume":"73","author":"Conaghan","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD012657-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/annrheumdis-2013-204761","article-title":"Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study","volume":"73","author":"Dougados","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7","key":"10.1002\/14651858.CD012657-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/rheumatology\/kes381","article-title":"Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial","volume":"52","author":"Doyle","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1002\/14651858.CD012657-BIB0040|cit40","first-page":"1069","article-title":"A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment","volume":"63","author":"Durez","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012657-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","article-title":"Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))","volume":"69","author":"Emery","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"19","key":"10.1002\/14651858.CD012657-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1316133","article-title":"Sustained remission with etanercept tapering in early rheumatoid arthritis","volume":"371","author":"Emery","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD012657-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s10067-014-2731-y","article-title":"Efficacy of golimumab plus methotrexate in methotrexate-na\u00efve patients with severe active rheumatoid arthritis","volume":"33","author":"Emery","year":"2014","journal-title":"Clinical Rheumatology"},{"issue":"19","key":"10.1002\/14651858.CD012657-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1316133","article-title":"Sustained remission with etanercept tapering in early rheumatoid arthritis","volume":"371","author":"Emery","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/annrheumdis-2013-205060","article-title":"Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial","volume":"74","author":"Eriksson","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD012657-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012657-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/ard.2008.099291","article-title":"Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study","volume":"68","author":"Fleischmann","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD012657-BIB0049|cit49","first-page":"S577","article-title":"2-year results from the Ample (Abatacept versus adalimumab comparison in biologic-na\u00efve RA patients with background methotrexate) trial: changes in patient-reported outcomes in response to subcutaneous abatacept or adalimumab in rheumatoid arthritis","volume":"65","author":"Fleischmann","year":"2013","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012657-BIB0050|cit50","first-page":"2563","article-title":"Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)","volume":"30","author":"Furst","year":"2003","journal-title":"Journal of Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD012657-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/ard.2006.068304","article-title":"Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study","volume":"66","author":"Furst","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD012657-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/acr.22496","article-title":"Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis","volume":"67","author":"Furst","year":"2015","journal-title":"Arthritis Care & Research"},{"issue":"9877","key":"10.1002\/14651858.CD012657-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD012657-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5455\/medarh.2014.68.51-53","article-title":"Treatment of rheumatoid arthritis with biologic DMARDS (rituximab and etanercept)","volume":"68","author":"Gashi","year":"2014","journal-title":"Medical Archives"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","article-title":"Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes","volume":"46","author":"Genovese","year":"2002","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012657-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis and Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD012657-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012657-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","article-title":"Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1002\/art.30463","article-title":"Subcutaneous abatacept versus intravenous abatacept: a phase IIIb non-inferiority study in patients with an inadequate response to methotrexate","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis and Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD012657-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1136\/annrheumdis-2013-204760","article-title":"Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study","volume":"73","author":"Genovese","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012657-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/annrheumdis-2014-eular.1798","article-title":"THU0229\u2005Association of radiographic damage with physical function in patients with rheumatoid arthritis \u2013 results from the RAPID1 Trial","volume":"73","author":"Gherge","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","article-title":"Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial","volume":"146","author":"Goekoop-Ruiterman","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD012657-BIB0063|cit63","first-page":"1464","article-title":"Clinical and radiographic outcomes with etanercept and etanercept and methotrexate in patients with rheumatoid arthritis: two-year results from the Canadian methotrexate and etanercept outcome study (CAMEO)","volume":"65","author":"Haraoui","year":"2014","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1002\/14651858.CD012657-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/annrheumdis-2013-203243","article-title":"A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study","volume":"73","author":"Heimans","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s40064-015-0895-9","article-title":"Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy","volume":"4","author":"Hobbs","year":"2015","journal-title":"Springerplus"},{"issue":"1","key":"10.1002\/14651858.CD012657-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/annrheumdis-2014-205752","article-title":"Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study","volume":"74","author":"Huizinga","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1002\/14651858.CD012657-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/annrheumdis-2012-202735","article-title":"Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial","volume":"73","author":"H\u00f8rslev-Petersen","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD012657-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3899\/jrheum.130658","article-title":"Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial","volume":"41","author":"Iannone","year":"2014","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0069|cit69","first-page":"659","article-title":"Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study","volume":"33","author":"Johnsen","year":"2006","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/annrheumdis-2011-200344","article-title":"Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study)","volume":"71","author":"Kaine","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD012657-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3899\/jrheum.110014","article-title":"Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study","volume":"38","author":"Kameda","year":"2011","journal-title":"Journal of Rheumatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012657-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/annrheumdis-2014-eular.2007","article-title":"Effect of certolizumab pegol on workplace and household productivity in US patients with rheumatoid arthritis with or without prior anti-tumor necrosis factor exposure: results from the predict study","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD012657-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.23383","article-title":"Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"58","author":"Kay","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD012657-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s13075-014-0467-3","article-title":"Efficacy and safety of pateclizumab (anti-lymphotoxin-alpha) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)","volume":"16","author":"Kennedy","year":"2014","journal-title":"Arthritis Research & Therapy"},{"issue":"5","key":"10.1002\/14651858.CD012657-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","article-title":"Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/art.20019","article-title":"Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis and Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"785\u201393","DOI":"10.1002\/art.23715","article-title":"Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti\u2013tumor necrosis factor therapy","volume":"59","author":"Keystone","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD012657-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3899\/jrheum.130489","article-title":"Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment","volume":"41","author":"Keystone","year":"2014","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1479-8077.2007.00248.x","article-title":"A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate","volume":"10","author":"Kim","year":"2007","journal-title":"APLAR Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD012657-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1756-185X.2011.01680.x","article-title":"Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial","volume":"15","author":"Kim","year":"2012","journal-title":"International Journal of Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.3346\/jkms.2013.28.12.1716","article-title":"A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment","volume":"28","author":"Kim","year":"2013","journal-title":"Journal of Korean Medical Science"},{"issue":"11","key":"10.1002\/14651858.CD012657-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/acr.22384","article-title":"Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis","volume":"66","author":"Kivitz","year":"2014","journal-title":"Arthritis Care Research"},{"key":"10.1002\/14651858.CD012657-BIB0084|cit84","first-page":"S365","article-title":"Effect of rituximab therapy on life quality with rheumatoid arthritis patients","volume":"25","author":"Koroleva","year":"2014","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD012657-BIB0085|cit85","first-page":"S374","article-title":"The effect of rituximab therapy on bone mineral density with rheumatoid arthritis patients","volume":"25","author":"Koroleva","year":"2014","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD012657-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","article-title":"Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig","volume":"349","author":"Kremer","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD012657-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.21201","article-title":"Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial","volume":"52","author":"Kremer","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"12","key":"10.1002\/14651858.CD012657-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD012657-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD012657-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.30158","article-title":"Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year","volume":"63","author":"Kremer","year":"2011","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13075-015-0612-7","article-title":"Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial","volume":"17","author":"Kremer","year":"2015","journal-title":"Arthritis Research & Therapy"},{"issue":"8","key":"10.1002\/14651858.CD012657-BIB0092|cit92","first-page":"618","article-title":"A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study","volume":"103","author":"Lan","year":"2004","journal-title":"Journal of the Formosan Medical Association"},{"key":"10.1002\/14651858.CD012657-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13075-015-0626-1","article-title":"Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis","volume":"17","author":"Landewe","year":"2015","journal-title":"Arthritis Research Therapy"},{"issue":"22","key":"10.1002\/14651858.CD012657-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012657-BIB0095|cit95","first-page":"394","article-title":"Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks","volume":"35","author":"Lisbona","year":"2008","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard.2009.116277","article-title":"Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept","volume":"69","author":"Lisbona","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD012657-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/RHU.0000000000000055","article-title":"Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region","volume":"20","author":"Machado","year":"2014","journal-title":"Journal of Clinical Rheumatology"},{"issue":"9194","key":"10.1002\/14651858.CD012657-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012657-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13075-015-0630-5","article-title":"Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial","volume":"17","author":"Manders","year":"2015","journal-title":"Arthritis Research Therapy"},{"issue":"1","key":"10.1002\/14651858.CD012657-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0149-2918(00)87984-9","article-title":"Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo","volume":"22","author":"Mathias","year":"2000","journal-title":"Clinical Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD012657-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.10294","article-title":"Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion","volume":"46","author":"Moreland","year":"2002","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/ard.2009.126573","article-title":"Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA","volume":"69","author":"Nam","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/1471-2474-15-452","article-title":"The \u2018Switch\u2019 study protocol: a randomised controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug","volume":"15","author":"Navarro Coy","year":"2014","journal-title":"BMC Musculoskeletal Disorders"},{"issue":"1","key":"10.1002\/14651858.CD012657-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/s10165-008-0125-1","article-title":"Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy","volume":"19","author":"Nishimoto","year":"2009","journal-title":"Modern Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD012657-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1303006","article-title":"Therapies for active rheumatoid arthritis after methotrexate failure","volume":"369","author":"O'Dell","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012657-BIB0107|cit107","first-page":"S211","article-title":"A randomised controlled trial evaluating the effect of humira upon endothelial function in ACPA positive rheumatoid arthritis: an interim analysis","volume":"66","author":"Oakley","year":"2014","journal-title":"Arthritis and Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD012657-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s10067-013-2240-4","article-title":"Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study","volume":"32","author":"Pavelka","year":"2013","journal-title":"Clinical Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1136\/annrheumdis-2013-203684","article-title":"The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis.","volume":"73","author":"Pope","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD012657-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/03009740410005467","article-title":"Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate","volume":"33","author":"Rau","year":"2004","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD012657-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/acr.20419","article-title":"Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate","volume":"63","author":"Rigby","year":"2011","journal-title":"Arthritis Care and Research"},{"issue":"9","key":"10.1002\/14651858.CD012657-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/rheumatology\/keq116","article-title":"Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)","volume":"49","author":"Rubbert-Roth","year":"2010","journal-title":"Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/art.20277","article-title":"The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions","volume":"50","author":"Schiff","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012657-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"8","author":"Schiff","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial","volume":"73","author":"Schiff","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9617","key":"10.1002\/14651858.CD012657-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2008.090019","article-title":"Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade","volume":"68","author":"Smolen","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9870","key":"10.1002\/14651858.CD012657-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","article-title":"Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial","volume":"381","author":"Smolen","year":"2013","journal-title":"Lancet"},{"issue":"9914","key":"10.1002\/14651858.CD012657-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(13)61751-1","article-title":"Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial","volume":"383","author":"Smolen","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD012657-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD012657-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/annrheumdis-2013-204632","article-title":"Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial","volume":"74","author":"Smolen","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD012657-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/rheumatology\/ket466","article-title":"Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events","volume":"53","author":"Sonomoto","year":"2014","journal-title":"Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD012657-BIB0123|cit123","first-page":"234","article-title":"Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials","volume":"14","author":"Strand","year":"2008","journal-title":"American Journal of Managed Care"},{"issue":"1","key":"10.1002\/14651858.CD012657-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3899\/jrheum.101161","article-title":"Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study","volume":"39","author":"Strand","year":"2012","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD012657-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2011-200170","article-title":"Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial","volume":"71","author":"Tak","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD012657-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Research"},{"key":"10.1002\/14651858.CD012657-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.2011.200317","article-title":"Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study","volume":"71","author":"Tanaka","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD012657-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/art.20123","article-title":"Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis","volume":"50","author":"Taylor","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD012657-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/art.21544","article-title":"Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD012657-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"Heijde","year":"2013","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1002\/14651858.CD012657-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1136\/ard.2008.093294","article-title":"Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis","volume":"68","author":"Kooij","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9688","key":"10.1002\/14651858.CD012657-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","article-title":"Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial","volume":"374","author":"Vollenhoven","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012657-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"Vollenhoven","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012657-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(12)60027-0","article-title":"Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial","volume":"379","author":"Vollenhoven","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/annrheumdis-2013-204544","article-title":"An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial","volume":"74","author":"Vital","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012657-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","article-title":"Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"228\u201334","DOI":"10.1136\/ard.2006.055111","article-title":"Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7","key":"10.1002\/14651858.CD012657-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1921\u201330","DOI":"10.1002\/art.23493","article-title":"Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week","volume":"58","author":"Weinblatt","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012657-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/kes150","article-title":"Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study","volume":"51","author":"Weinblatt","year":"2012","journal-title":"Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD012657-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1136\/annrheumdis-2013-203742","article-title":"Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial","volume":"73","author":"Weinblatt","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0149-2918(03)80164-9","article-title":"Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study","volume":"25","author":"Weisman","year":"2003","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD012657-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/rheumatology\/kem033","article-title":"A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases","volume":"46","author":"Weisman","year":"2007","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/art.21734","article-title":"The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial","volume":"54","author":"Westhovens","year":"2006","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/annrheumdis-2014-eular.3819","article-title":"Health-related quality of life of patients with rheumatoid arthritis achieving DAS28 remission, improvement in physical function and no radiographic progression","volume":"73","author":"Westhovens","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD012657-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3109\/14397595.2013.843764","article-title":"Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial","volume":"24","author":"Yamamoto","year":"2014","journal-title":"Modern Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD012657-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/rheumatology\/ket465","article-title":"Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial","volume":"53","author":"Yamanaka","year":"2014","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/ard.2010.148700","article-title":"Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study","volume":"71","author":"Yazici","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1479-8077.2006.00186.x","article-title":"Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China","volume":"9","author":"Zhang","year":"2006","journal-title":"APLAR Journal of Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD012657-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2474-9-52","article-title":"Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and meta analysis of efficacy and safety","volume":"9","author":"Alonso-Ruiz","year":"2008","journal-title":"BMC Musculoskeletal Disorders"},{"issue":"3","key":"10.1002\/14651858.CD012657-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012657-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0738-3991(98)00144-X","article-title":"Comparison of knowledge and psychological well-being between patients with a short disease duration (< or = 1 year) and patients with more established rheumatoid arthritis (> or = 10 years duration)","volume":"38","author":"Barlow","year":"1999","journal-title":"Patient Education and Counseling"},{"key":"10.1002\/14651858.CD012657-BIB0155|cit155","unstructured":"Becker LA Oxman AD Chapter 22: Overviews of Reviews. In: Higgins JP, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012657-BIB0156|cit156","first-page":"405-14, x","article-title":"Treatment of early disease","volume":"27","author":"Boers","year":"2001","journal-title":"Rheumatic Diseases Clinics of North America"},{"issue":"19","key":"10.1002\/14651858.CD012657-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"7","key":"10.1002\/14651858.CD012657-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/ard.2008.094904","article-title":"Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials","volume":"68","author":"Bongartz","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0159|cit159","first-page":"1\u201312","article-title":"Impact of tofacitinib on patient outcomes in rheumatoid arthritis \u2013 review of clinical studies","volume":"7","author":"Boyce","year":"2016","journal-title":"Patient Related Outcome Measures"},{"key":"10.1002\/14651858.CD012657-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"Bradburn","year":"2007","journal-title":"Statistics in Medicine"},{"issue":"11","key":"10.1002\/14651858.CD012657-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1172\/JCI36389","article-title":"Evidence that cytokines play a role in rheumatoid arthritis","volume":"118","author":"Brennan","year":"2008","journal-title":"Journal of Clinical Investigation"},{"key":"10.1002\/14651858.CD012657-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"681678","DOI":"10.1155\/2014\/681678","article-title":"B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers","volume":"2014","author":"Bugatti","year":"2014","journal-title":"BioMed Research International"},{"issue":"19","key":"10.1002\/14651858.CD012657-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJM199405123301908","article-title":"Second-line drug therapy for rheumatoid arthritis","volume":"330","author":"Cash","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012657-BIB0164|cit164","unstructured":"Dr Chris Cates' EBM website. Available from www.Nntonline.Net\/visualrx\/ Visual Rx NNT Calculator version 3"},{"issue":"12","key":"10.1002\/14651858.CD012657-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choy","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD012657-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/ard.2005.048975","article-title":"Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities","volume":"65","author":"Chung","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD012657-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.berh.2006.05.011","article-title":"New cytokine targets in inflammatory rheumatic diseases","volume":"20","author":"Connell","year":"2006","journal-title":"Best Practice and Research Clinical Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2412","article-title":"T cells in rheumatoid arthritis","volume":"10 Suppl 1","author":"Cope","year":"2008","journal-title":"Arthritis Research and Therapy"},{"issue":"2","key":"10.1002\/14651858.CD012657-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: an update","volume":"28","author":"DerSimonian","year":"2007","journal-title":"Contemporary Clinical Trials"},{"issue":"11","key":"10.1002\/14651858.CD012657-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1345\/aph.1R203","article-title":"Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis","volume":"46","author":"Desai","year":"2012","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD012657-BIB0171|cit171","unstructured":"Dias S Welton NJ Sutton AJ Caldwell DM Lu G Ades AE NICE Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials. 1\u201339 (2011) Available at www.nicedsu.org.uk"},{"issue":"2","key":"10.1002\/14651858.CD012657-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"124","DOI":"10.7326\/0003-4819-148-2-200801150-00192","article-title":"Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis","volume":"148","author":"Donahue","year":"2008","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD012657-BIB0173|cit173","unstructured":"Drug Information Online. Drugs.com FDA Approves First Rheumatoid Arthritis Indication for Rituxan www.drugs.com\/news\/fda-approves-first-rheumatoid-arthritis-indication-rituxan-1745.html"},{"key":"10.1002\/14651858.CD012657-BIB0174|cit174","unstructured":"European Medicines Agency EMA Public Statement on infliximab (Remicade): increased incidence of mortality and hospitalization for worsening congestive heart failure www.ema.europa.eu\/docs\/en_GB\/document_library\/Public_statement\/2009\/12\/WC500018442.pdf"},{"key":"10.1002\/14651858.CD012657-BIB0175|cit175","unstructured":"European Medicines Agency EMA public statement: Increased risk of serious infection and neutropenia in patients treated concurrently with Kineret (anakinra) and Enbrel (etanercept) www.ema.europa.eu\/docs\/en_GB\/document_library\/Public_statement\/2009\/12\/WC500018427.pdf"},{"key":"10.1002\/14651858.CD012657-BIB0176|cit176","unstructured":"European Medicines Agency EPARs for authorized medicinal products for human use: Anakinra: European Public Assessment Report www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000363\/WC500042440.pdf"},{"key":"10.1002\/14651858.CD012657-BIB0177|cit177","unstructured":"European Medicines Agency Remicade (inflixmab) www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000240\/WC500050883.pdf"},{"key":"10.1002\/14651858.CD012657-BIB0178|cit178","unstructured":"European Medicines Agency EPARs for authorized medicinal products for human use: Humira: European Public Assessment Report www.emea.europa.eu\/humandocs\/Humans\/EPAR\/humira\/humira.htm"},{"key":"10.1002\/14651858.CD012657-BIB0179|cit179","article-title":"Drugs@FDA: FDA Approved Drug Products - Rituxan","author":"Food","year":"1997","journal-title":"www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&applno=103705"},{"key":"10.1002\/14651858.CD012657-BIB0180|cit180","unstructured":"Food Drug Administration Drugs@FDA: FDA Approved Drug Products - Remicade www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&applno=103772 1998"},{"key":"10.1002\/14651858.CD012657-BIB0181|cit181","unstructured":"Food Drug Administration Drugs@FDA: FDA Approved Drug Products - Enbrel www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&applno=103795 1998"},{"key":"10.1002\/14651858.CD012657-BIB0182|cit182","unstructured":"Food Drug Administration Drugs@FDA: FDA Approved Drug Products - Kineret www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&applno=103950 2001"},{"key":"10.1002\/14651858.CD012657-BIB0183|cit183","unstructured":"Food Drug Administration Drugs@FDA: FDA Approved Drug Products - Humira www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/adalabb123102lb.htm 2002"},{"key":"10.1002\/14651858.CD012657-BIB0184|cit184","unstructured":"Food Drug Administration Drugs@FDA: FDA Approved Drug Products - Orencia www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&applno=125118 2005"},{"key":"10.1002\/14651858.CD012657-BIB0185|cit185","unstructured":"Food Drug Administration Rituxan\u00ae (rituximab) www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm126519.htm"},{"key":"10.1002\/14651858.CD012657-BIB0186|cit186","unstructured":"Food Drug Administration Drugs@FDA: FDA Approved Drug Products - Cimzia www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&applno=125160 2008"},{"key":"10.1002\/14651858.CD012657-BIB0187|cit187","unstructured":"Food Drug Administration FDA: Manufacturers of TNF-blocker drugs must highlight risk of fungal infections www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124185.htm#"},{"key":"10.1002\/14651858.CD012657-BIB0188|cit188","unstructured":"Food Drug Administration Drugs@FDA: FDA Approved Drug Products - Simponi www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&applno=125289 2009"},{"key":"10.1002\/14651858.CD012657-BIB0189|cit189","unstructured":"Food Drug Administration Drugs@FDA: FDA Approved Drug Products - Actemra www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&applno=125276 2010"},{"key":"10.1002\/14651858.CD012657-BIB0190|cit190","unstructured":"Food Drug Administration Drugs@FDA: FDA Approved Drug Products - Xeljanz www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&applno=203214 2012"},{"key":"10.1002\/14651858.CD012657-BIB0191|cit191","unstructured":"Food Drug Administration Rituxan (rituximab) Label www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/103705s5432lbl.pdf 2014"},{"key":"10.1002\/14651858.CD012657-BIB0192|cit192","unstructured":"Food Drug Administration Risk evaluation and mitigation strategy (REMS). NDA 203,214 XELJANZ\u00ae (tofacitinib) www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM330290.pdf"},{"key":"10.1002\/14651858.CD012657-BIB0193|cit193","unstructured":"Food Drug Administration Remicade\u00ae (infliximab) Label www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/103772s5374lbl.pdf 2015"},{"key":"10.1002\/14651858.CD012657-BIB0194|cit194","unstructured":"Food Drug Administration Kineret (anakinra) Label www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/103950s5175lbl.pdf 2016"},{"key":"10.1002\/14651858.CD012657-BIB0195|cit195","unstructured":"Food Drug Administration Enbrel\u00ae (etanercept) Label www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/103795s5552lbl.pdf 2016"},{"key":"10.1002\/14651858.CD012657-BIB0196|cit196","unstructured":"Food Drug Administration Orencia (abatacept) Label www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125118s211lbl.pdf 2017"},{"key":"10.1002\/14651858.CD012657-BIB0197|cit197","unstructured":"Food Drug Administration Humira (adalimumab) Label www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125057s399lbl.pdf 2017"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/art.22353","article-title":"Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis","volume":"55","author":"Finckh","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"5 Suppl 39","key":"10.1002\/14651858.CD012657-BIB0200|cit200","first-page":"S93","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"23","author":"Fransen","year":"2005","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD012657-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis and Rheumatism"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012657-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1136\/ard.2008.100834","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008","volume":"67 Suppl 3","author":"Furst","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"Suppl 1:i2-29","DOI":"10.1136\/ard.2009.123885","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases 2009","volume":"69","author":"Furst","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012657-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1136\/annrheumdis-2011-201036","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases 2011","volume":"71","author":"Furst","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9877","key":"10.1002\/14651858.CD012657-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD012657-BIB0206|cit206","first-page":"2398","article-title":"The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis","volume":"33","author":"Gartlehner","year":"2006","journal-title":"The Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD012657-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3899\/jrheum.121306","article-title":"Updated method guidelines for Cochrane Musculoskeletal Group systematic reviews and metaanalyses","volume":"41","author":"Ghogomu","year":"2014","journal-title":"The Journal of Rheumatology"},{"issue":"7651","key":"10.1002\/14651858.CD012657-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012657-BIB0209|cit209","unstructured":"Health Canada Important safety information on anti-TNF\u03b1 therapy: Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab) - for health professionals http:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2006\/14389a-eng.php"},{"key":"10.1002\/14651858.CD012657-BIB0210|cit210","unstructured":"Health Canada Possible association of Remicade (infliximab) with hepatosplenic T-cell lymphoma in pediatric and young adult patients with Crohn's disease - for health professionals http:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2006\/14201a-eng.php"},{"key":"10.1002\/14651858.CD012657-BIB0211|cit211","unstructured":"Health Canada Association of Enbrel (etanercept) with histoplasmosis and other invasive fungal infections - for health professionals http:\/\/www.healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2009\/14545a-eng.php"},{"key":"10.1002\/14651858.CD012657-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012657-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012657-BIB0214|cit214","unstructured":"Higgins JP Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). C ochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"10","key":"10.1002\/14651858.CD012657-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Annals of Internal Medicine"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD012657-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200422001-00002","article-title":"Epidemiology and burden of illness of rheumatoid arthritis","volume":"22","author":"Kvien","year":"2004","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1002\/14651858.CD012657-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/03009740500327727","article-title":"Quality of life in rheumatoid arthritis","volume":"34","author":"Kvien","year":"2005","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/028418517701800415","article-title":"Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films","volume":"4","author":"Larsen","year":"1977","journal-title":"Acta Radiologica: Diagnosis"},{"issue":"9285","key":"10.1002\/14651858.CD012657-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","article-title":"Rheumatoid arthritis","volume":"358","author":"Lee","year":"2001","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00296-007-0475-6","article-title":"Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis","volume":"28","author":"Lee","year":"2008","journal-title":"Rheumatology International"},{"issue":"25","key":"10.1002\/14651858.CD012657-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD012657-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events","volume":"68","author":"Leombruno","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD012657-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00019053-200422001-00004","article-title":"Patient-reported outcomes and their role in the assessment of rheumatoid arthritis","volume":"22","author":"Lubeck","year":"2004","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"10.1002\/14651858.CD012657-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jclinepi.2013.02.004","article-title":"The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses","volume":"66","author":"Mustafa","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/ard.2009.126573","article-title":"Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA","volume":"69","author":"Nam","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/sim.2624","article-title":"Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis","volume":"26","author":"Nixon","year":"2007","journal-title":"Statistics in Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/03009740510018633","article-title":"Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register","volume":"34","author":"Odegard","year":"2005","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0228|cit228","first-page":"429","article-title":"Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70","volume":"6","author":"Orme","year":"2012","journal-title":"Biologics: targets & therapy"},{"key":"10.1002\/14651858.CD012657-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.62.4.316","article-title":"Number needed to treat (NNT): implication in rheumatology clinical practice","volume":"62","author":"Osiri","year":"2003","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD012657-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/art.1780261107","article-title":"Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire","volume":"26","author":"Pincus","year":"1983","journal-title":"Arthritis and Rheumatism"},{"issue":"12","key":"10.1002\/14651858.CD012657-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/rheumatology\/41.12.1346","article-title":"Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review","volume":"41","author":"Pincus","year":"2002","journal-title":"Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD012657-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/rheumatology\/35.11.1101","article-title":"Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score","volume":"35","author":"Prevoo","year":"1996","journal-title":"British Journal of Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012657-BIB0234|cit234","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan5) 2014"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0235|cit235","first-page":"762","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis & Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD012657-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0962280207080643","article-title":"Evaluation of networks of randomized trials","volume":"17","author":"Salanti","year":"2008","journal-title":"Statistical Methods in Medical Research"},{"key":"10.1002\/14651858.CD012657-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"8","author":"Schiff","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7","key":"10.1002\/14651858.CD012657-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMct055183","article-title":"Tumor necrosis factor inhibitors for rheumatoid arthritis","volume":"355","author":"Scott","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/art.1780140605","article-title":"Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities","volume":"14","author":"Sharp","year":"1971","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD012657-BIB0240|cit240","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007848.pub2","article-title":"Biologics for rheumatoid arthritis: an overview of Cochrane Reviews","author":"Singh","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD012657-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Research"},{"issue":"1","key":"10.1002\/14651858.CD012657-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0243|cit243","doi-asserted-by":"crossref","unstructured":"Singh Jasvinder A Hossain Alomgir Tanjong G Elizabeth Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis Cochrane Database of Systematic Reviews 2016 10.1002\/14651858.CD012183","DOI":"10.1002\/14651858.CD012183"},{"issue":"11","key":"10.1002\/14651858.CD012657-BIB0244|cit244","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012437","article-title":"Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA)","author":"Singh","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012657-BIB0245|cit245","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012591","article-title":"Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis","author":"Singh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012657-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012657-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses","volume":"326","author":"Song","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012657-BIB0248|cit248","unstructured":"Spiegelhalter D Thomas A Best N WinBUGS user manual. Version 1.4, January 2003. MRC Biostat. Unit 2. faculty.washington.edu\/jmiyamot\/p548\/spiegelhalter%20winbugs%20user%20manual.pdf. 2003"},{"issue":"4","key":"10.1002\/14651858.CD012657-BIB0249|cit249","first-page":"234","article-title":"Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials","volume":"14(4)","author":"Strand","year":"2008","journal-title":"American Journal of Managed Care"},{"key":"10.1002\/14651858.CD012657-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012657-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/BOR.0b013e32805e87ae","article-title":"Macrophages and their products in rheumatoid arthritis","volume":"19","author":"Szekanecz","year":"2007","journal-title":"Current Opinion in Rheumatology"},{"issue":"20","key":"10.1002\/14651858.CD012657-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V","article-title":"Explaining heterogeneity in meta-analysis: a comparison of methods","volume":"18","author":"Thompson","year":"1999","journal-title":"Statistics in Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012657-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/art.30310","article-title":"Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"63","author":"Thompson","year":"2011","journal-title":"Arthritis & Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD012657-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews","volume":"41","author":"Turner","year":"2012","journal-title":"International Journal of Epidemiology"},{"issue":"8646","key":"10.1002\/14651858.CD012657-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(89)92442-2","article-title":"Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis","volume":"1","author":"Heijde","year":"1989","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD012657-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/art.37711","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study","volume":"65","author":"Weinblatt","year":"2013","journal-title":"Arthritis & Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD012657-BIB0257|cit257","first-page":"557","article-title":"Minimum important difference between patients with rheumatoid arthritis: the patient's perspective","volume":"20","author":"Wells","year":"1993","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD012657-BIB0258|cit258","unstructured":"Wells GA Sultan SA Chen L Khan M Coyle D Indirect evidence: indirect treatment comparisons in meta-analysis Canadian Agency for Drugs and Technologies in Health. Ottawa 2009"},{"issue":"17","key":"10.1002\/14651858.CD012657-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMcibr023206","article-title":"The mast cell in inflammatory arthritis","volume":"348","author":"Woolley","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012657-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/BOR.0b013e3280126b66","article-title":"Work disability in rheumatic diseases","volume":"19","author":"Yelin","year":"2007","journal-title":"Current Opinion in Rheumatology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012657\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T09:07:31Z","timestamp":1750237651000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012657"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,5,8]]},"references-count":260,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012657","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,8]]}}}